Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon?

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more rapidly progressive variant steatohepatitis (MASH) are widespread chronic liver conditions linked to obesity and other common metabolic disorders. The emergence of tirzepatide, a dual incretin receptor agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, presents major therapeutic potential for MASLD. This review article explores the mechanisms of action of tirzepatide, highlighting its ability to improve glycemic control, promote weight loss, and potentially ameliorate hepatic steatosis and fibrosis. Recent studies suggest that tirzepatide may offer significant benefits in managing MASLD/MASH by modulating metabolic pathways and enhancing liver health. However, further research is needed to fully understand its long-term impact on MASLD/MASH progression and outcomes across diverse patient populations.

Keywords

metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) / dual incretin receptor antagonist / glucose-dependent insulinotropic polypeptide (GIP) / glucagon-like peptide-1 (GLP-1) / type 2 diabetes mellitus / obesity / tirzepatide

References

[1] Lonardo A, Weiskirchen R. Liver and obesity: a narrative review. Explor Med. 2025; 6: 1001334.

[2] Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction—associated steatotic liver disease. Clin Mol Hepatol. 2025; 31: S32-50.

[3] Chandrasekaran P, Weiskirchen R. The Role of Obesity in Type 2 Diabetes Mellitus—An Overview. Int J Mol Sci. 2024; 25: 1882.

[4] El K, Douros JD, Willard FS, Novikoff A, Sargsyan A, Perez—Tilve D, et al. The incretin co—agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat Metab. 2023; 5: 945-54.

[5] Coskun T, Sloop KW, Loghin C, Alsina—Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP—1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018; 18: 3-14.

[6] Farzam K, Patel P. Tirzepatide. Cham: Treasure Island (FL): StatPearls Publishing LLC; 2025.

[7] PubChem [Internet]. Bethesda (MD): National Library of Medicine (US); c2025 [cited 2025 Jul 10]. Available from: https://pubchem.ncbi.nlm.nih.gov/

[8] RCSB Protein Data Bank [Internet]. New Jersey: RCSB Protein Data Bank; c2025 [cited 2025 Jul 10]. Available from: https://www.rcsb.org/

[9] Sun B, Willard FS, Feng D, Alsina—Fernandez J, Chen Q, Vieth M, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022; 119: e2116506119.

[10] Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. ; SYNERGY—NASH Investigators. Tirzepatide for Metabolic Dysfunction—Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024; 391: 299-310.

[11] Hu W, Gong W, Yang F, Cheng R, Zhang G, Gan L, et al. Dual GIP and GLP—1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice. Int Immunopharmacol. 2025; 147: 113937.

[12] Targher G, Valenti L, Byrne CD. Metabolic Dysfunction—Associated Steatotic Liver Disease. N Engl J Med. 2025; 393: 683-98.

[13] Liarakos AL, Koliaki C. Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game—Changers or Great Expectations? A Narrative Review. Biomedicines. 2023; 11: 1875.

[14] Cho YM, Kieffer TJ. K—cells and glucose—dependent insulinotropic polypeptide in health and disease. Vitam Horm. 2010; 84: 111-50.

[15] Kuhre RE, Deacon CF, Holst JJ, Petersen N. What Is an L—Cell and How Do We Study the Secretory Mechanisms of the L—Cell? Front Endocrinol (Lausanne). 2021; 12: 694284.

[16] Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP—1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021; 23: 5-29.

[17] Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon—like peptide—1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024; 9: 234.

[18] Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP—1 receptor agonist. JCI Insight. 2020; 5: e140532.

[19] Al—Horani RA, Chedid M. Tirzepatide: A New Generation Therapeutic for Diabetes Type 2. Endocr Metab Immune Disord Drug Targets. 2023; 23: 1046-50.

[20] Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023; 46: 998-1004.

[21] Corrao S, Pollicino C, Maggio D, Torres A, Argano C. Tirzepatide against obesity and insulin—resistance: pathophysiological aspects and clinical evidence. Front Endocrinol (Lausanne). 2024; 15: 1402583.

[22] Zaïmia N, Obeid J, Varrault A, Sabatier J, Broca C, Gilon P, et al. GLP—1 and GIP receptors signal through distinct β—arrestin 2—dependent pathways to regulate pancreatic β cell function. Cell Rep. 2023; 42: 113326.

[23] Kamrul—Hasan ABM, Mondal S, Dutta D, Nagendra L, Kabir MR, Pappachan JM. Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta—Analysis. Obes Sci Pract. 2024; 10: e70032.

[24] Dutta P, Kumar Y, Babu AT, Ravindran SG, Salam A, Rai B, et al. Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond. Cureus. 2023; 15: e38379.

[25] Sokary S, Bawadi H. The promise of tirzepatide: A narrative review of metabolic benefits. Prim Care Diabetes. 2025; 19: 229-37.

[26] He Z, Gao Y, Lieu L, Afrin S, Cao J, Michael NJ, et al. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons — Implications for energy balance and glucose control. Mol Metab. 2019; 28: 120-34.

[27] McMorrow HE, Lorch CM, Hayes NW, Fleps SW, Frydman JA, Xia JL, et al. Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite. BioRxiv 585583 [Preprint]. 2024 [cited 2025 Jul 10]. Available from: https://www.biorxiv.org/content/10.1101/2024.03.18.585583v1

[28] Eren—Yazicioglu CY, Yigit A, Dogruoz RE, Yapici—Eser H. Can GLP—1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front Behav Neurosci. 2021; 14: 614884.

[29] Thondam SK, Cuthbertson DJ, Wilding JPH. The influence of Glucose—dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non—Alcoholic Fatty Liver Disease (NAFLD). Peptides. 2020; 125: 170208.

[30] Xu F, Lin B, Zheng X, Chen Z, Cao H, Xu H, et al. GLP—1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. Diabetologia. 2016; 59: 1059-69.

[31] Simental—Mendía LE, Simental—Mendía M, Barragán—Zúñiga LJ, Navarro—Tinoco L. Effect of tirzepatide on leptin and adiponectin levels. Eur J Intern Med. 2024; 130: 168-70.

[32] Lonardo A, Weiskirchen R. From Hypothalamic Obesity to Metabolic Dysfunction—Associated Steatotic Liver Disease: Physiology Meets the Clinics via Metabolomics. Metabolites. 2024; 14: 408.

[33] Chandrasekaran P, Weiskirchen R. Cellular and Molecular Mechanisms of Insulin Resistance. Curr Tissue Microenvironm Rep. 2024; 5: 79-90.

[34] Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long—acting activation of the GIP receptor. Cell Metab. 2024; 36: 1534-49.

[35] Ferhatbegović L, Mršić D, Macić—Džanković A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc. 2023; 4: 1293926.

[36] Bosch C, Carriazo S, Soler MJ, Ortiz A, Fernandez—Fernandez B. Tirzepatide and prevention of chronic kidney disease. Clin Kidney J. 2022; 16: 797-808.

[37] Zoncapè M, Liguori A, Tsochatzis EA. Non—invasive testing and risk—stratification in patients with MASLD. Eur J Intern Med. 2024; 122: 11-9.

[38] Dawod S, Brown K. Non—invasive testing in metabolic dysfunction—associated steatotic liver disease. Front Med (Lausanne). 2024; 11: 1499013.

[39] Ferdous SE, Ferrell JM. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction—Associated Steatotic Liver Disease: Novel Therapeutic Approaches. Int J Mol Sci. 2024; 25: 8731.

[40] Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS—3 MRI): a substudy of the randomised, open—label, parallel—group, phase 3 SURPASS—3 trial. Lancet Diabetes Endocrinol. 2022; 10: 393-406.

[41] Sawamura T, Mizoguchi R, Ohmori A, Kometani M, Yoneda T, Karashima S. Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study. J Diabetes Metab Disord. 2024; 23: 2105—13.

[42] Ferch M, Peitsch I, Kautzky—Willer A, Greber—Platzer S, Stättermayer AF, Krebs M, et al. Effectiveness of the Dual GIP/GLP1—Agonist Tirzepatide in 2 Cases of Alström syndrome, a Rare Obesity Syndrome. J Clin Endocrinol Metab. 2025;[Epub ahead of print].

[43] Sattar N, Neeland IJ, Leinhard OD, Landó LF, Bray R, Linge J, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS—3 MRI): a post—hoc analysis of a randomised, open—label, parallel—group, phase 3 trial. Lancet Diabetes Endocrinol. 2025; 13: 482-93.

[44] Okuma H. Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction—Associated Steatotic Liver Disease: A Retrospective Cohort Study. Cureus. 2025; 17: e83712.

[45] Oe Y, Omori T, Aimono E, Furukawa S, Kitakawa H, Tateno M, et al. Case Report: Amelioration of severe metabolic dysfunction—associated steatohepatitis after switching from conventional GLP—1RAs to tirzepatide. Front Endocrinol (Lausanne). 2025; 16: 1501984.

[46] Souza M, Al—Sharif L, Antunes VLJ, Huang DQ, Loomba R. Comparison of pharmacological therapies in metabolic dysfunction—associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta—analysis. Hepatology. 2025;[Epub ahead of print].

[47] Wang Y, Zhou Y, Wang Z, Ni Y, Prud’homme GJ, Wang Q. Efficacy of GLP—1—based Therapies on Metabolic Dysfunction—Associated Steatotic Liver Disease and Metabolic Dysfunction—Associated Steatohepatitis: A Systematic Review and Meta—Analysis. J Clin Endocrinol Metab. 2025;[Epub ahead of print].

[48] Machado MV. MASLD treatment—a shift in the paradigm is imminent. Front Med (Lausanne). 2023; 10: 1316284.

[49] Weiskirchen R, Lonardo A. How ‘miracle’ weight—loss semaglutide promises to change medicine but can we afford the expense? Br J Pharmacol. 2025; 182: 1651-70.

[50] Morales E, Martin WP, Bevc S, Jenssen TG, Miglinas M, Trillini M. How to individualise renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA. Nephrol Dial Transplant. 2025;[Epub ahead of print].

[51] Njei B, Al—Ajlouni Y, Lemos SY, Ugwendum D, Ameyaw P, Njei LP, et al. Efficacy and Safety of GLP—1 Receptor Agonists in Patients With Metabolic Dysfunction—Associated Steatotic Liver Disease: A Systematic Review and Meta—Analysis of Randomized Controlled Trials. Cureus. 2024; 16: e71366.

[52] Andraos J, Muhar H, Smith SR. Beyond glycemia: Comparing tirzepatide to GLP—1 analogues. Rev Endocr Metab Disord. 2023; 24: 1089-101.

[53] Cherubini A, Torre SD, Pelusi S, Valenti L. Sexual dimorphism of metabolic dysfunction—associated steatotic liver disease. Trends Mol Med. 2024; 30: 1126—36.

[54] Burra P, Zanetto A, Germani G. Sex bias in clinical trials in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol. 2022; 19: 413—4.

[55] Lonardo A, Ballestri S, Mantovani A, Targher G, Bril F. Endpoints in NASH Clinical Trials: Are We Blind in One Eye? Metabolites. 2024; 14: 40.

[56] Dileo E, Saba F, Parasiliti—Caprino M, Rosso C, Bugianesi E. Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction—Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies. Nutrients. 2025; 17: 477.

[57] Terrington I, Thomas K, Stone H, Coad J, Khakoo S. Idiosyncratic acute liver failure induced by Tirzepatide. J Gastrointestin Liver Dis. 2024; 33: 574—5.

[58] Phox M, Thesing J, Kilgore WR 3rd, Alderson J. Tirzepatide—Induced Liver Injury: A Rare Medication Side Effect. ACG Case Rep J. 2025; 12: e01661.

[59] Zepbound (tirzepatide) FDA Approval History [Internet]. Drugs.com; c2000— 2025 [cited 2025 Jul 10]. Available from: https://www.drugs.com/history/zepbound.html#:~:text=Tirzepatide%20was%20first%20approved%20under,with%20type%202%20diabetes%20mellitus

[60] Chen H, Ding Y, Shan Y. Post—marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database. Expert Opin Drug Saf. 2025; 24: 959-67.

[61] Klein JA, St—Pierre J, Choi D, Lopez J, Rubin DT. Dramatic Changes in Thiopurine Metabolite Levels in a Patient With Inflammatory Bowel Disease Treated With Tirzepatide for Weight Loss. ACG Case Rep J. 2024; 11: e01544.

[62] Lonardo A. Resmetirom: Finally, the light at the end of the NASH tunnel? Livers. 2024; 4: 138—41.

[63] Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol. 2022; 20: 1354-61.e7.

[64] Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double—blind, placebo—controlled phase 3 trial. Nat Med. 2023; 29: 2919-28.

[65] Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide—1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022; 23: 521—39.

[66] Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP—1 receptor agonist—based therapies and cardiovascular risk: a review of mechanisms. J Endocrinol. 2024; 263: e240046.

[67] Ludvik B, Giorgino F, Jódar E, Frias JP, Landó LF, Brown K, et al. Once—weekly tirzepatide versus once—daily insulin degludec as add—on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS—3): a randomised, open—label, parallel—group, phase 3 trial. Lancet. 2021; 398: 583-98.

[68] Huttasch M, Roden M, Kahl S. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? Metabolism. 2024; 157: 155937.

[69] Newsome PN, Loomba R. Therapeutic horizons in metabolic dysfunction—associated steatohepatitis. J Clin Invest. 2025; 135: e186425.

[70] Kim HY, Rinella ME. Emerging therapies and real—world application of metabolic dysfunction—associated steatotic liver disease treatment. Clin Mol Hepatol. 2025; 31: 753-70.

[71] Matz—Soja M, Berg T, Kietzmann T. Sex—Related Variations in Liver Homeostasis and Disease: From Zonation Dynamics to Clinical Implications. J Hepatol. 2025;[Epub ahead of print].

[72] Jamalinia M, Lonardo A, Weiskirchen R. Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes. Fibrosis. 2024; 2: 10006.

[73] Lonardo A, Stefan N, Mantovani A. Widening research horizons on metabolic dysfunction—associated steatotic liver disease and cancer. Trends Endocrinol Metab. 2025; 36: 610—3.

[74] Jamalinia M, Zare F, Mantovani A, Targher G, Lonardo A. Metabolic dysfunction—associated steatotic liver disease and sex—specific risk of fatal and non—fatal cardiovascular events: A meta—analysis. Diabetes Obes Metab. 2025; 27: 5171-81.

[75] Dutta D, Surana V, Singla R, Aggarwal S, Sharma M. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP—1 receptor agonist in the management of type—2 diabetes: A Cochrane meta—analysis. Indian J Endocrinol Metab. 2021; 25: 475-89.

[76] Targher G. Tirzepatide adds hepatoprotection to its armoury. Lancet Diabetes Endocrinol. 2022; 10: 374-5.

[77] Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med. 2021; 10: 492.

[78] Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther. 2021; 38: 2130—58.

[79] Lonardo A. The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers. Expert Rev Clin Pharmacol. 2023; 16: 891-911.

[80] O’Hearn M, Lauren BN, Wong JB, Kim DD, Mozaffarian D. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999—2018. J Am Coll Cardiol. 2022; 80: 138-51.